Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - hklaw.com
Court of Appeals affirmed a judgment striking down an FDA rule that would have required pharmaceutical ads to disclose drug prices.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) that advertise prescription drugs. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The rule mandating price disclosure in pharmaceutical ads remains invalid; no price disclosure is currently required.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) that advertise prescription drugs.
What you must do
No immediate action required; continue current advertising practices without price disclosure.
Deadline
Not specified.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court bans Florida compounder from all manufacturing until it can meet FDA requirements - fiercepharma.com
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - foleyhoag.com
- FDA finalizes rule change allowing mail-order abortion pills - pbs.org
- FDA sends warning letter to Regener-Eyes for cGMP violations, unapproved new drugs - Glance by Eyes On Eyecare
- FDA warning letter flags serious violations at New Jersey manufacturing facility for GLP-1 weight loss jabs - cleanroomtechnology.com